Health Funding Solutions

Creating consistency in a public funding program improving access to additional 11% patients​

Improving indications for recombinant Ab therapy increasing market share by 8%​

Launching an end-to-end patient management program and including a rare genetic disease under public coverage​

Redirect mainly public funds towards certain disease areas through:​

Redesigning BIM and tying-it up to government strategies and reposition the value of a drug rather than its cost​

Creating solutions of efficiencies in the public healthcare system improving reimbursement and consistency​

Wrapping up technology around pharmaceutical solutions to increase market share​